ES2584183T3 - Formulaciones de cladribina para suministro mejorado oral y transmucosa - Google Patents
Formulaciones de cladribina para suministro mejorado oral y transmucosa Download PDFInfo
- Publication number
- ES2584183T3 ES2584183T3 ES04758440.4T ES04758440T ES2584183T3 ES 2584183 T3 ES2584183 T3 ES 2584183T3 ES 04758440 T ES04758440 T ES 04758440T ES 2584183 T3 ES2584183 T3 ES 2584183T3
- Authority
- ES
- Spain
- Prior art keywords
- cyclodextrin
- cladribine
- transmucosal delivery
- improved oral
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title abstract 4
- 229960002436 cladribine Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 abstract 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
- 0 N*CC(C1)C1N Chemical compound N*CC(C1)C1N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
Abstract
Una composición farmacéutica que comprende un complejo saturado de cladribina-ciclodextrina formulado en una forma de dosis oral sólida, dicha composición esta sustancialmente libre de ciclodextrina en exceso de la cantidad mínima requerida para maximizar la cantidad de cladribina en el complejo o para mantener sustancialmente toda la cladribina en el complejo, en donde la ciclodextrina es γ-ciclodextrina o hidroxipropil-ß-ciclodextrina y en donde la proporción en peso de cladribina a ciclodextrina es de 1:35 a 1:50.
Description
81
91
12
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45892203P | 2003-03-28 | 2003-03-28 | |
US458922P | 2003-03-28 | ||
US48475603P | 2003-07-02 | 2003-07-02 | |
US484756P | 2003-07-02 | ||
US54124604P | 2004-02-04 | 2004-02-04 | |
US541246P | 2004-02-04 | ||
PCT/US2004/009384 WO2004087100A2 (en) | 2003-03-28 | 2004-03-26 | Cladribine formulations for improved oral and transmucosal delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2584183T3 true ES2584183T3 (es) | 2016-09-26 |
Family
ID=33135981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04758440.4T Expired - Lifetime ES2584183T3 (es) | 2003-03-28 | 2004-03-26 | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
Country Status (16)
Country | Link |
---|---|
US (2) | US20070065492A1 (es) |
EP (1) | EP1608343B1 (es) |
JP (1) | JP5412709B2 (es) |
KR (1) | KR20060011943A (es) |
CN (1) | CN101912615B (es) |
AU (2) | AU2004226435B2 (es) |
BR (1) | BRPI0408895A (es) |
CA (1) | CA2520522C (es) |
EA (1) | EA009714B1 (es) |
ES (1) | ES2584183T3 (es) |
HR (1) | HRP20050924A2 (es) |
IS (1) | IS8047A (es) |
ME (1) | MEP34508A (es) |
MX (1) | MXPA05010330A (es) |
NO (1) | NO20054944L (es) |
WO (1) | WO2004087100A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2263678B1 (en) | 2004-12-22 | 2014-06-11 | Merck Serono SA | Cladribine regimen for treating early secondary progressive Multiple Sclerosis |
CA2590471A1 (en) * | 2004-12-22 | 2006-06-29 | Laboratoires Serono S.A. | Combination treatment for multiple sclerosis |
US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
PL2026832T3 (pl) | 2006-05-24 | 2012-08-31 | Merck Serono Sa | Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego |
CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
CN100486645C (zh) * | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
EP2106786A1 (de) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
DK2919791T3 (da) | 2012-11-15 | 2017-07-17 | Sapiotec Gmbh | Delphinidin-kompleks som antiflogistisk eller immunsuppressivt aktivt stof |
US9511047B2 (en) | 2012-12-11 | 2016-12-06 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
WO2015140790A1 (en) * | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
BR112020010282A2 (pt) | 2017-11-24 | 2020-11-17 | Merck Patent Gmbh | regime de cladribina para uso no tratamento de formas progressivas de esclerose múltipla |
AU2021342333A1 (en) | 2020-09-10 | 2023-04-06 | Merck Patent Gmbh | Novel treatment regimen for the treatment of autoimmune disorders |
GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
CA3209648A1 (en) | 2021-03-03 | 2022-09-09 | Ursula BOSCHERT SHAFAATIAN | Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods |
RU2758436C1 (ru) * | 2021-04-05 | 2021-10-28 | Общество с ограниченной ответственностью «ФармЭко» | Способ получения аморфных ко-эвапоратов кладрибина с циклодекстринами |
WO2023242285A1 (en) | 2022-06-15 | 2023-12-21 | Vektor Pharma Tf Gmbh | Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
HU181703B (en) | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
JPS5838250A (ja) * | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | 複合体 |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
JPS58177949A (ja) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | ランカシジン群抗生物質包接化合物 |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
DE3317064A1 (de) | 1983-05-10 | 1984-11-15 | Consortium für elektrochemische Industrie GmbH, 8000 München | Verfahren zur herstellung von cyclooctaamylose |
DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5106837A (en) * | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
US4920214A (en) | 1986-04-16 | 1990-04-24 | American Maize-Products Company | Process for producing modified cyclodextrins |
JPS62281855A (ja) * | 1986-05-29 | 1987-12-07 | Daikin Ind Ltd | ビタミン,ビタミン誘導体,またはホルモンを含有する包接化合物 |
JP2575460B2 (ja) * | 1988-05-12 | 1997-01-22 | 東京田辺製薬株式会社 | ダナゾール−シクロデキストリン包接化合物 |
ES2116982T3 (es) | 1989-04-03 | 1998-08-01 | Janssen Pharmaceutica Nv | Sustituciones regioselectivas en ciclodextrinas. |
JPH035438A (ja) * | 1989-05-31 | 1991-01-11 | Kaken Pharmaceut Co Ltd | フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤 |
JPH07507775A (ja) * | 1992-05-19 | 1995-08-31 | ザ スクリップス リサーチ インスティテュート | 慢性骨髄性白血病の治療薬としての2−ハロアデニン誘導体の使用 |
US5424296A (en) * | 1993-04-15 | 1995-06-13 | The Scripps Research Institute | 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma |
US5510336A (en) * | 1994-09-06 | 1996-04-23 | Saven; Alan | 2-halo-2'-deoxyadenosine treatment for histiocytosis |
SK67298A3 (en) * | 1995-11-23 | 1998-11-04 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
JPH10265495A (ja) * | 1997-03-25 | 1998-10-06 | Meiji Milk Prod Co Ltd | フルオロプロゲステロン誘導体包接化合物 |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
EP0940157A3 (de) | 1998-01-29 | 2000-06-14 | Hans Werner Prof. Lorenzen | Vorrichtung zur Stimulation von Körpergewebe |
US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
US6239118B1 (en) * | 1999-10-05 | 2001-05-29 | Richard A. Schatz | Method for preventing restenosis using a substituted adenine derivative |
US7141555B2 (en) * | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
BRPI0408848B8 (pt) * | 2003-03-28 | 2021-07-27 | Ares Trading Sa | composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação |
-
2004
- 2004-03-26 WO PCT/US2004/009384 patent/WO2004087100A2/en active Application Filing
- 2004-03-26 US US10/551,094 patent/US20070065492A1/en not_active Abandoned
- 2004-03-26 CA CA2520522A patent/CA2520522C/en not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408895-6A patent/BRPI0408895A/pt not_active IP Right Cessation
- 2004-03-26 KR KR1020057018337A patent/KR20060011943A/ko not_active Application Discontinuation
- 2004-03-26 AU AU2004226435A patent/AU2004226435B2/en not_active Expired
- 2004-03-26 MX MXPA05010330A patent/MXPA05010330A/es active IP Right Grant
- 2004-03-26 ES ES04758440.4T patent/ES2584183T3/es not_active Expired - Lifetime
- 2004-03-26 JP JP2006509370A patent/JP5412709B2/ja not_active Expired - Lifetime
- 2004-03-26 EP EP04758440.4A patent/EP1608343B1/en not_active Expired - Lifetime
- 2004-03-26 EA EA200600403A patent/EA009714B1/ru not_active IP Right Cessation
- 2004-03-26 CN CN2010101265463A patent/CN101912615B/zh not_active Expired - Lifetime
- 2004-03-26 ME MEP-345/08A patent/MEP34508A/xx unknown
-
2005
- 2005-09-26 IS IS8047A patent/IS8047A/is unknown
- 2005-10-25 HR HR20050924A patent/HRP20050924A2/xx not_active Application Discontinuation
- 2005-10-25 NO NO20054944A patent/NO20054944L/no not_active Application Discontinuation
-
2009
- 2009-10-15 AU AU2009227811A patent/AU2009227811B2/en not_active Expired
-
2010
- 2010-09-27 US US12/891,492 patent/US8623408B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2004087100A2 (en) | 2004-10-14 |
EP1608343A2 (en) | 2005-12-28 |
US8623408B2 (en) | 2014-01-07 |
AU2004226435B2 (en) | 2009-11-12 |
AU2004226435A1 (en) | 2004-10-14 |
JP2006526009A (ja) | 2006-11-16 |
NO20054944D0 (no) | 2005-10-25 |
WO2004087100A3 (en) | 2005-03-03 |
AU2009227811B2 (en) | 2012-02-02 |
HRP20050924A2 (en) | 2006-08-31 |
EP1608343B1 (en) | 2016-04-27 |
CN101912615B (zh) | 2013-03-27 |
AU2009227811A1 (en) | 2009-11-05 |
US20070065492A1 (en) | 2007-03-22 |
IS8047A (is) | 2005-09-26 |
EA009714B1 (ru) | 2008-02-28 |
MEP34508A (en) | 2011-02-10 |
KR20060011943A (ko) | 2006-02-06 |
CN101912615A (zh) | 2010-12-15 |
US20110015145A1 (en) | 2011-01-20 |
CA2520522A1 (en) | 2004-10-14 |
CA2520522C (en) | 2012-05-29 |
BRPI0408895A (pt) | 2006-04-11 |
NO20054944L (no) | 2005-11-24 |
MXPA05010330A (es) | 2006-05-31 |
JP5412709B2 (ja) | 2014-02-12 |
EA200600403A1 (ru) | 2006-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2584183T3 (es) | Formulaciones de cladribina para suministro mejorado oral y transmucosa | |
AR110010A2 (es) | Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo | |
CR9626A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato | |
AR070356A1 (es) | Producto para cuidado oral y metodos de uso del mismo | |
AR065887A1 (es) | Producto para el cuidado oral y metodos de uso y fabricacion de los mismos | |
ECSP11004868A (es) | Capsulas para inhalación | |
BR0314271A (pt) | Forma de dosagem oral sólida útil para administração oral transmucosal, e, métodos de reduzir apetências por nicotina, e, uso de tabaco | |
CY1115190T1 (el) | Φαρμακοτεχνικες μορφες αερολυματων περιλαμβανοντας διενυδρη φουμαρικη φορμοτερολη, ενα προωθητικο, αιθανολη και προεραιτικως ενα στεροειδες, οπου η διενυδρη φουμαρικη φορμοτερολη εχει ενα περιεχομενο υδατος του 4,8-4.28% κατα βαρος | |
EA200600598A1 (ru) | Лекарственные формы замедленного высвобождения | |
CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
PA8472901A1 (es) | Formulaciones farmaceuticas | |
CY1106774T1 (el) | Συνθεσεις φαρμακευτικων μεσων με βαση αλατα του τιοτροπιου και αλατα της σαλμετερολης | |
AR055319A1 (es) | Derivados de isoquinoleina, composiciones farmaceuticas y usos | |
BRPI0713481B8 (pt) | composição farmacêutica de liberação controlada na forma de dosagem sólida, polímero linear, e, método para produzir um polímero linear | |
NO20052490D0 (no) | Dagsdoseringsenheter for melatonin. | |
ES2530791T3 (es) | Formulación de ibandronato de altas dosis | |
CL2008000610A1 (es) | Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor. | |
BRPI0413676A (pt) | composto, e, composição farmacêutica | |
ES2132778T3 (es) | Polvos de resina de organopolisiloxano, proceso para su preparacion y su empleo en composiciones de organopolisiloxanos. | |
DE602006009259D1 (de) | Pharmazeutische zusammensetzung mit einem organopoirkstoff | |
ATE326985T1 (de) | Lyophilisierte pharmazeutische zusammensetzung von propofol | |
UY28154A1 (es) | Composiciones y metodos de cuidado oral | |
BRPI0408848A (pt) | formulações orais de cladribine | |
AR029637A1 (es) | Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento | |
AR046213A1 (es) | Forma de presentacion del naproxeno sodico |